The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research
Abstract
ONJ has been increasingly suspected to be a potential complication of bisphosphonate therapy in recent years. Thus, the ASBMR leadership appointed a multidisciplinary task force to address key questions related to case definition, epidemiology, risk factors, diagnostic imaging, clinical management, and future areas for research related to the disorder. This report summarizes the findings and recommendations of the task force. Introduction: The increasing recognition that use of bisphosphonates may be associated with osteonecrosis of the jaw (ONJ) led the leadership of the American Society for Bone and Mineral Research (ASBMR) to appoint a task force to address a number of key questions related to this disorder. Materials and Methods: A multidisciplinary expert group reviewed all pertinent published data on bisphosphonate-associated ONJ. Food and Drug Administration drug adverse event reports were also reviewed. Results and Conclusions: A case definition was developed so that subsequent studies could report on the same condition. The task force defined ONJ as the presence of exposed bone in the maxillofacial region that did not heal within 8 wk after identification by a health care provider. Based on review of both published and unpublished data, the risk of ONJ associated with oral bisphosphonate therapy for osteoporosis seems to be low, estimated between 1 in 10,000 and <1 in 100,000 patient-treatment years. However, the task force recognized that information on incidence of ONJ is rapidly evolving and that the true incidence may be higher. The risk of ONJ in patients with cancer treated with high doses of intravenous bisphosphonates is clearly higher, in the range of 1–10 per 100 patients (depending on duration of therapy). In the future, improved diagnostic imaging modalities, such as optical coherence tomography or MRI combined with contrast agents and the manipulation of image planes, may identify patients at preclinical or early stages of the disease. Management is largely supportive. A research agenda aimed at filling the considerable gaps in knowledge regarding this disorder was also outlined.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The risk of ONJ appears to increase with duration of treatment beyond 5 years [77].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [77]
Citations
Cites
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Self-citationMarx, R. E., Sawatari, Y., Fortin, M., & Broumand, V. (2005) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2005.07.010 · Cited by 1,648 · cited 1×
“P (5) A + P (1) Max (5) Marx et al.((23)) 3 O (3) A (3) Marunick et al.”
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252 · cited 2×
“● Surgical management: ● Surgical treatment should be conservative or delayed.((12,37,38))”
BackgroundSelf-citationOsteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8670 · Cited by 1,149 · cited 1×
“However, for those who received zoledronic acid alone, the hazard was 1% within the first year but rose to 21% at 3 yr.((18))”
BackgroundHillner, B. E., Ingle, J. N., Chlebowski, R. T., Gralow, J., Yee, G. C., Janjan, N. A., Cauley, J. A., Blumenstein, B. A., Albain, K. S., Lipton, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.017 · Cited by 970
Self-citationOsteonecrosis of the Jaw and Bisphosphonates
(2005) · New England Journal of Medicine · doi:10.1056/nejm200507073530120 · Cited by 744
Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia
Mavrokokki, T., Cheng, A., Stein, B., & Goss, A. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.10.061 · Cited by 650
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542 · cited 2×
“The American Society of Clinical Oncology (ASCO) has established guidelines for the use of bisphosphonates in patients with metastatic breast cancer and multiple myeloma.((7,8)) The ASCO guidelines suggest that once the bisphosphonate is initiated, it should be continued until there is substantial decline in the patie…”
BackgroundRuggiero, S. L., Fantasia, J., & Carlson, E. (2006) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2006.06.004 · Cited by 507
Self-citationManaging the care of patients with bisphosphonate-associated osteonecrosis
MIGLIORATI, C. A., CASIGLIA, J., EPSTEIN, J., JACOBSEN, P. L., SIEGEL, M. A., & WOO, S.-B. (2005) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2005.0108 · Cited by 468
Self-citation
Research works printed but not linked: 3
- Felsenberg, 2006, Bisphosphonattherapie assoziierte, Kiefernekrosen Deutsches Arzteblatt, 46, A3078
- Van Poznak, 2004, Osteonecrosis of the maxilla and mandible in patients with metastatic breast cancer, J Bone Miner Res, 19, S227
- Ruggiero, 2004, Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, J Oral Maxillofac Surg, 62, 527, 10.1016/j.joms.2004.02.004 · DOI · Paper page
Cited by
Clinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149
“The risk of ONJ appears to increase with duration of treatment beyond 5 years [77].”
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Self-citationWells, S. A., Asa, S. L., Dralle, H., Elisei, R., Evans, D. B., Gagel, R. F., Lee, N., Machens, A., Moley, J. F., Pacini, F., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0335 · Cited by 2,444
“Side effects of these potent antiresorptives include osteonecrosis of the jaw, atypical subtrochanteric fractures, and hypocalcemia (323,324).”
Self-citationShane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Self-citation
Metadata
- Authors
- Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., McCauley, L. K., McGowan, J., McKee, M. D., Mohla, S., Pendrys, D. G., Raisz, L. G., Ruggiero, S. L., Shafer, D. M., Shum, L., Silverman, S. L., Van Poznak, C. H., Watts, N., Woo, S.-B., & Shane, E.
- Affiliations
- American Society for Bone and Mineral Research (US)
- ASBMR Task Force on Bisphosphonate-Associated ONJ
- Corresponding author
- Shane, Elizabeth
- ORCID
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-01
- Volume
- 22
- Issue
- 10
- Pages
- 1479-1491
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2150904792
- Cited by
- 1,650
- References
- 43
- Citations by year
- 2026: 20 · 2025: 40 · 2024: 41 · 2023: 35 · 2022: 52 · 2021: 45 · 2020: 71 · 2019: 58 · 2018: 58 · 2017: 70 · 2016: 89 · 2015: 114 · 2014: 121 · 2013: 152 · 2012: 118
- FWCI
- 69.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Journal of Bone and Mineral Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Procter and Gamble
- American Society for Bone and Mineral Research
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Dentistry › General Dentistry › Oral health in cancer treatment
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- bisphosphonate-related osteonecrosis of the jaw, bisphosphonates, osteonecrosis of the jaw, case definition, risk factors, oral bisphosphonates, osteoporosis, cancer patients, intravenous bisphosphonates, diagnostic imaging, optical coherence tomography, magnetic resonance imaging, clinical management, drug adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Americas, Animals, Diagnosis, Differential, Diphosphonates, Female, Humans, Jaw Diseases, Male, Middle Aged, Minerals, Osteonecrosis, Risk Factors, Societies, Medical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. https://app.cochat.ai/papers/10.1359/jbmr.0707onj
- The paper
- Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., McCauley, L. K., McGowan, J., McKee, M. D., Mohla, S., Pendrys, D. G., Raisz, L. G., Ruggiero, S. L., Shafer, D. M., Shum, L., . . . Shane, E. (2007). Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.0707onj
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.